A. Prete, Verena Theiler-Schwetz, Wiebke Arlt, Irina Chifu, Birgit Harbeck, Catherine Napier, John Newell-Price, Aled Rees, Nicole Reisch, Gunter K. Stalla, Naila Aslam, H. Coope, Kerry Maltby, John Porter, John Quirke, M. R. R. John
{"title":"CHAMPAIN 研究:关于改良释放型氢化可的松的疗效、安全性和耐受性的 II 期研究的初步结果:Chronocort® (Efmody®) 与 Plenadren® 在原发性肾上腺功能不全中的对比研究的初步结果","authors":"A. Prete, Verena Theiler-Schwetz, Wiebke Arlt, Irina Chifu, Birgit Harbeck, Catherine Napier, John Newell-Price, Aled Rees, Nicole Reisch, Gunter K. Stalla, Naila Aslam, H. Coope, Kerry Maltby, John Porter, John Quirke, M. R. R. John","doi":"10.1530/endoabs.99.rc3.4","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":502743,"journal":{"name":"Endocrine Abstracts","volume":"40 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CHAMPAIN study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency\",\"authors\":\"A. Prete, Verena Theiler-Schwetz, Wiebke Arlt, Irina Chifu, Birgit Harbeck, Catherine Napier, John Newell-Price, Aled Rees, Nicole Reisch, Gunter K. Stalla, Naila Aslam, H. Coope, Kerry Maltby, John Porter, John Quirke, M. R. R. John\",\"doi\":\"10.1530/endoabs.99.rc3.4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":502743,\"journal\":{\"name\":\"Endocrine Abstracts\",\"volume\":\"40 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrine Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1530/endoabs.99.rc3.4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/endoabs.99.rc3.4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CHAMPAIN study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency